5173 results about "Covalent bond" patented technology

The present invention relates to a molecular sustained controlled release system constructed by the conjugation of molecules to be released with biodegradable polyester polymer via covalent bond and method for preparation thereof. In accordance with the present invention, the system may be formulated into microspheres, nanoparticles, or films. The molecular release rate from the above system can be regulated to be proportional to the chemical degradation rate of the biodegradable polyester polymers, resulting in near zero order kinetics profile of release without showing a burst effect, Moreover, a high loading efficiency of hydrophilic drugs can be achieved.

Provision of a novel platinum complex which is useful as a material for a light-emitting device of good light emission characteristic and light emission efficiency, and a novel light-emitting material that may be utilized in various fields.

A platinum complex represented by the following general formula (1):

(in which two rings of ring A, ring B, ring C, and ring D represent nitrogen-containing heterocyclic rings which may have a substituent and the remaining two rings of them represent aryl rings or hetero aryl rings which may have a substituent, the ring A and the ring B, the ring A and the ring C or/and the ring B and the rind D may form condensed rings. Two of X¹, X², X³, and X⁴ represent nitrogen atoms coordination bonded to a platinum atom and the remaining two of them represent carbon atoms or nitrogen atoms. Q¹, Q², and Q³ each represents a bond, oxygen atom, sulfur atom or bivalent group, two of Z¹, Z², Z³, and Z⁴ represent coordination bonds, and the remaining two of them represent covalent bonds, oxygen atoms or sulfur atoms), and a light-emitting device containing the platinum complex.

Coupling of anodic electrochromic compounds by a covalent bond or a bridge link which provides for electronic communication between the coupled electrochromic compounds results in coupled electrochromic compounds which exhibit greater stability as well as electrochromic activity that differs from the monomeric electrochromic compounds. Extension of the absorption spectrum into the near-infrared region of the spectrum is frequently observed. The coupled electrochromic compounds are highly suitable for use in electrochromic media used to produce electrochromic devices.

Electroluminescent devices and materials including an electroluminescent organo-siloxane polymer. The main chain of the organo-siloxane polymer comprises an organic component that can be alkenyl, alkynyl, aralkyl, aryl, heteroaralkyl, and heteroaryl which can be substituted optionally with hydrogen, alkyl, aryl, heteroalkyl, heteroaralkyl, nitro, cyano, hydroxy, alkoxy, aryloxy, thio, alkylthio, arylthio, amino, halogen, dialkylamino, diarylamino, diaralkylamino, arylamino, alkylamino, arylalkylamino, carbonyloxy, carbonylalkoxy, carbonylalkyloxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxylcarbonyloxy, sulfonyl, or sulfonyloxy. The organic component includes at least two covalent bonds coupling the organic component to the main chain of the organo-siloxane polymer. Such devices provide superior performance and mechanical stability compared with conventional organic electroluminescent materials and devices made from such materials.

A method for protecting a peptide from peptidase activity in vivo, the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid and an N-terminus amino acid is described. In the first step of the method, the peptide is modified by attaching a reactive group to the C-terminus amino acid, to the N-terminus amino acid, or to an amino acid located between the N-terminus and the C-terminus, such that the modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component. In the next step, a covalent bond is formed between the reactive group and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting said peptide from peptidase activity. The final step of the method involves the analyzing of the stability of the peptide-blood component conjugate to assess the protection of the peptide from peptidase activity.

A conjugate of formula A-L-P, in which:

• • A represents a glycosylated/galactosylated peptide that binds to a cell-surface receptor,
  • L represents a bifunctional linker, which does not comprise a naturally occurring amino acid and is covalently bonded to A and P in a regiospecific manner, and
  • P represents a monomer, homopolymer or heteropolymer comprising at least one nucleotide or an analogue thereof, which inhibits the intracellular biosynthesis of nucleotides or nucleic acids in a sequence-independent manner,
  • wherein either or both of the covalent bond between A and L and the covalent bond between L and P can be cleaved intracellularly; a composition comprising such a conjugate; and a method of inhibiting abnormal cellular proliferation in a mammal; and a method of inhibiting replication of a virus in a mammal.

A photoacid compound having the following general structure:<paragraph lvl="0"><in-line-formula>R-O(CF2)nSO3X</in-line-formula>wherein n is an integer between about 1 to 4; R is selected from the group consisting of: substituted or unsubstituted C1-C12 linear or branched alkyl or alkenyl, substituted or unsubstituted araalkyl, substituted or unsubstituted aryl, substituted or unsubstituted bicycloalkyl, substituted or unsubstituted tricycloalkyl, hydrogen, alkyl sulfonic acid, substituted or unsubstituted perfluoroalkyl, the general structure F((CF2)pO)m(CF2)q- wherein p is between about 1 to 4, m is between about 0 to 3 and q is between about 1 to 4, and substituted or unsubstituted partially fluorinated alkyl, halofluoroalkyl, perfluoroalkylsulfonic, or glycidyl; and X is selected from the group consisting of: organic cations and covalently bonded organic radicals.

Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.

The invention provides a cost-effective method for making a silicone hydrogel contact lens having a hydrophilic coating thereon that is covalently attached to the lens and has a good hydrophilicity, intactness and durability. The invention also provides a silicone hydrogel contact lenses having a hydrophilic coating consisting of a prime coating covalently attached to the contact lens and a top coating covalently attached to the prime coating.

The invention provides for dendrimer conjugates useful for liver-specific delivery of therapeutic agents. The therapeutic agent is associated to the dendrimer through a enzyme-cleavable covalent linkage.

A platinum complex represented by the general formula (1) below, useful as a phosphorescence emission material, a tetradentate ligand useful for synthesizing the platinum complex, and a light-emitting device containing at least one of the platinum complex.

wherein ring B represents a nitrogen-containing aromatic heterocyclic ring; rings A, C and D each independently represent an aromatic or aromatic heterocyclic ring, while either of the rings C and D represents five-membered ring, the other represents a five- or six-membered ring; R^A, R^B, R^C, and R^D respectively represent substituents on the rings A, B, C, and D; two of X^A, X^B, X^C, and X^D represent a nitrogen atom that may be bound with the platinum atom by a coordinate bond, the others each independently represent a carbon atom or nitrogen atom that may be bound with the platinum atom by a covalent bond; Q represents a bivalent atom or atomic group bridging the rings B and C; and Y^C and Y^D each independently represent a carbon atom or nitrogen atom.

A semiconductor device having a semiconductor layer, includes: a first impurity atom having a covalent bond radius larger than a minimum radius of a covalent bond of a semiconductor constituent atom of a semiconductor layer; and a second impurity atom having a covalent bond radius smaller than a maximum radius of the covalent bond of the semiconductor constituent atom; wherein the first and second impurity atoms are arranged in a nearest neighbor lattice site location and at least one of the first and second impurity atoms is electrically active.

A security paper indicates exposure to a solvent by a solvent resistant color signal. A metal mordant dye first co-reactant and a mordant dye second co-reactant form an organic solvent-insoluble colored reaction product when the paper is washed with an organic solvent. The metal mordant dye first co-reactant and a mordant dye second co-reactant are chemically isolated from each other so as to prevent the coordinate covalent bond from forming until the paper is washed with an organic solvent. The chemical isolation can be effected by encapsulation or other physical separation of the co-reactants. The organic solvent-insoluble colored reaction product, once formed, remains entrapped in the web when the paper is washed with an organic solvent. The chemical isolation prevents the organic solvent-insoluble colored reaction product from forming upon the application of pressure alone to the paper.

The present invention relates to covalently bonded fullerene-functionalized carbon nanotubes (CBFFCNTs), a method and an apparatus for their production and to their end products. CBFFCNTs are carbon nanotubes with one or more fullerenes or fullerene based molecules covalently bonded to the nanotube surface. They are obtained by bringing one or more catalyst particles, carbon sources and reagents together in a reactor.

Improved compositions comprise a polymer and carbon fibers, such as nanotubes. In some embodiments, the carbon fibers, e.g., nanotubes, can be mechanically blended or incorporated into the polymer, while in some embodiments carbon nanotubes also may be covalently bonded to the polymer to form corresponding covalent materials. In particular, the polymer can be covalently bonded to the side walls of the carbon nanotubes to form a composite with particularly desirable mechanical properties. Specifically, the bonding of the polymer to the nanotube sidewall can provide desirable mechanical properties of the composite due to the orientation relative to other types of association between the nanotubes and the polymer. The processing of the nanotubes can be facilitated by the dispersion of the nanotubes in an aqueous solution comprising a hydrophylic polymer, such as ethyl vinyl acetate. A dispersion of nanotubes can be combined with a polymer in an extrusion process to blend the materials under high shear, such as in an extruder. In general, various articles can be formed that take advantage of the properties of the composite materials incorporating a polymer and carbon fibers, such as carbon nanotubes.

A method for reducing odor is provided. In one embodiment, the method comprises modifying the surface of silica particles with a transition metal so that the silica particles are bonded to the transition metal through a covalent or coordinate bond. The method further comprises contacting the modified silica particles with an odorous compound, the transition metal facilitating the capture of the odorous compound.

This invention provides a process for producing major histocompatibility antigen class II protein (hereinafter referred to as "MHC class II" for short) which occurs on the surfaces of antigen-presenting cells and the like, and MHC class II-bound materials in which MHC class II, alpha and/or beta subunit of MHC class II, or a part thereof is bound to a carrier such as beads, fibers and hollow fibers via covalent bond, as well as a module for removing superantigen using the same. This invention also provides a method for detecting or quantifying superantigens using MHC class II or a part thereof having an affinity to the superantigens, as well as an assay kit therefor.

The invention provides an organic/inorganic hybrid material with a high refractive index at telecommunications wavelengths. Energy curable compositions of the present invention include condensed metal oxide nanoparticles, a high refractive index organometallic coupling agent, an energy curable organometallic coupling agent, and a high refractive index monomer or oligomer. Polymeric materials of the present invention include condensed metal oxide nanoparticles having a mixture of organometallic coupling agents covalently bound to the exterior surface of the nanoparticles and a high refractive index solid polymer matrix, wherein the mixture of organometallic coupling agents includes a high refractive index coupling agent, and a coupling agent covalently bound to the polymer matrix. The materials of the present invention are useful in making optical devices for telecommunications applications.

Mixed matrix membranes are prepared from zeolites and polymers, such as polyimides, in a void free fashion where either no voids or voids of less than several Angstroms are present at the interface of the polymer and the zeolite by bonding (hydrogen, ionic, or covalent) functional groups on the zeolite with functional groups on the polymer. The mixed matrix membranes may be cast or formed by ISAM processes, and may be present on a variety of supports including hollow fibers.

A prodrug composition is provided which includes a pharmaceutical species and an amino acid having a covalent bond to the pharmaceutical species. The pharmaceutical species is characterized by bioavailability of 30% or less and a molecular weight in the range of 100-1000 Daltons. The composition is characterized further in that the pharmaceutical species is not acyclovir, ganciclovir, BRL44385, or penciclovir. Also described is an inventive method of delivering a pharmaceutical species to an individual including the step of orally administering an inventive prodrug to an individual. In one embodiment the prodrug includes a pharmaceutical species characterized by bioavailability of 30% or less, wherein the pharmaceutical species has a molecular weight in the range of 100-1000 Daltons. The inventive prodrug is transported from the gastrointestinal lumen by a specific transporter and is enzymatically cleaved to yield the pharmaceutical species, such that the pharmaceutical species is delivered to the individual.

The present invention relates to a biodegradable and thermosensitive poly(organophosphazene) with a functional group, a preparation method thereof, and a use thereof for delivery of bioactive substances. According to the present invention, poly(organophosphazene) is a phosphagen-based polymer showing biodegradability, thermosensitivity, and sol-gel phase transition depending on temperature change, whereby when administered into a living body with bioactive substances such as drugs, the poly(organophosphazene) forms a gel-phase at body temperature to be capable of controlled release of the bioactive substances. Further, the poly(organophosphazene) has functional groups to chemically bind with bioactive substances through an ionic bond, covalent bond, or coordinate covalent bond to be capable of a sustained release of the bioactive substances due to its good binding property. Therefore, the poly(organophosphazene) is useful as a delivery material for bioactive substances.